Immune checkpoint inhibitors plus VEGF tyrosine kinase inhibitors as second-line or later therapy for patients with extensive stage small cell lung cancer

被引：0

作者：

Yan, N. ^{[1
]}

Guo, S. X. ^{[1
]}

Li, M. J. ^{[1
]}

Huang, S. Y. ^{[1
]}

Guo, Q. Q. ^{[1
]}

Geng, D. ^{[1
]}

Zhang, H. X. ^{[1
]}

Li, X. ^{[2
]}

机构：

[1] Zhengzhou Sch Med, Affiliate Hosp 1, Oncol Dept, Zhengzhou, Peoples R China

[2] Zhengzhou Univ, Affiliated Hosp 1, Med Oncol, Zhengzhou, Peoples R China

来源：

ANNALS OF ONCOLOGY | 2021年 / 32卷

关键词：

D O I：

10.1016/j.annonc.2021.08.243

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

1659P

引用

页码：S1168 / S1168

页数：1

共 50 条

[41] Immune Checkpoint Inhibitors and Chemoradiation for Limited-Stage Small Cell Lung Cancer
Schlick, Brian
Shields, Misty Dawn
Marin-Acevedo, Julian A.
Patel, Ishika
Pellini, Bruna
CURRENT TREATMENT OPTIONS IN ONCOLOGY, 2022, 23 (08) : 1104 - 1120
[42] Role of Immune Checkpoint Inhibitors in Small Cell Lung Cancer
Cooper, Maryann R.
Alrajhi, Abdullah M.
Durand, Cheryl R.
AMERICAN JOURNAL OF THERAPEUTICS, 2018, 25 (03) : E349 - E356
[43] Optimization of second-line targeted therapy for metastatic renal cell carcinoma cancer after use of VEGF receptor - tyrosine kinase inhibitors (literature review)
Sarkor, R. V.
ONKOUROLOGIYA, 2012, 8 (04): : 22 - 26
[44] Ramucirumab plus atezolizumab in patients with stage IV non-small cell lung cancer previously treated with immune checkpoint inhibitors
Herzog, Brett H.
Waqar, Saiama N.
Devarakonda, Siddhartha
Ward, Jeffrey P.
Gao, Feng
Govindan, Ramaswamy
Morgensztern, Daniel
LUNG CANCER, 2022, 173 : 101 - 106
[45] Outcomes of second-line chemotherapy in patients with relapsed extensive small cell lung cancer
Froeschl, Sandra
Nicholas, Garth
Gallant, Victor
Laurie, Scott A.
JOURNAL OF THORACIC ONCOLOGY, 2008, 3 (02) : 163 - 169
[46] Immune checkpoint inhibitors in first-line therapy of advanced non-small cell lung cancer
Remon, Jordi
Besse, Benjamin
CURRENT OPINION IN ONCOLOGY, 2017, 29 (02) : 97 - 104
[47] Sintilimab combined with anlotinib and chemotherapy as second-line or later therapy in extensive-stage small cell lung cancer: a phase II clinical trial
Han, Xiao
Guo, Jun
Li, Lingyu
Huang, Yong
Meng, Xue
Wang, Linlin
Zhu, Hui
Meng, Xiangjiao
Shao, Qian
Li, Xing
Zhang, Yan
Wang, Jin
Chen, Yanhua
Zhang, Yingjie
Chen, Yiru
Zhu, Changbin
Wang, Zhehai
SIGNAL TRANSDUCTION AND TARGETED THERAPY, 2024, 9 (01)
[48] Perioperative Therapy for Non-Small Cell Lung Cancer with Immune Checkpoint Inhibitors
Soh, Junichi
Hamada, Akira
Fujino, Toshio
Mitsudomi, Tetsuya
CANCERS, 2021, 13 (16)
[49] Immune checkpoint inhibitors in therapy of non-small cell lung cancer (a review)
Kolesnik, O. P.
Mykhailychenko, V. V.
ZAPOROZHYE MEDICAL JOURNAL, 2021, 23 (03) : 418 - 425
[50] Efficacy and safety of immune checkpoint inhibitors plus recombinant human endostatin therapy as second-line treatment in advanced non-small-cell lung cancer with negative driver gene: a pilot study
Yang, Bo
Li, Yuzhi
Deng, Jie
Yang, Hui
Sun, Xiang
FRONTIERS IN ONCOLOGY, 2023, 13

← 1 2 3 4 5 →